Curriculum Vitae

Prof Gavin I.W. Galasko

BM BCh MA DM (Oxon) FRCP

CONSULTANT INTERVENTIONAL CARDIOLOGIST
LANCASHIRE CARDIAC CENTRE, BLACKPOOL

DIRECTOR OF RESEARCH, DEVELOPMENT AND INNOVATION,
BLACKPOOL TEACHING HOSPITALS NHS FOUNDATION TRUST

HONORARY PROFESSOR OF CARDIOLOGY,
LANCASTER UNIVERSITY

April 2025

PERSONAL DETAILS

Nationality: British **Age:** 53
GMC No: 4215253 (full with specialist registration)

Work Address: Lancashire Cardiac Centre
Blackpool Teaching Hospitals NHS Foundation Trust
Whinney Heys Road
Blackpool, Lancashire
FY3 8NR

Tel: 01253 957761
Email: dr.galasko@nhs.net

POSITIONS HELD	**Dates**
Director of the National NIHR Commercial Research Delivery Centre, Blackpool	2025 -
Honorary Professor of Cardiology, Lancaster University	2024 -
ICB/Cardiac Network Lipid Lead for Lancashire and South Cumbria	2022-23
Member of the NIHR NWC Research Alignment Group	2022 - 24
Member of the Lancashire and South Cumbria Cardiac Network	2022 -
Member of the NIHR PRC Programme Board	2021-23
Director of the National NIHR Patient Recruitment Centre, Blackpool	2020 - 25
Honorary Senior Research Fellow, University of Salford	2018 -
Director of Research, Development and Innovation, Blackpool Teaching Hospitals	2017 -
Honorary Senior Lecturer, Liverpool University Medical School	2016 - 24
Honorary Lecturer, Liverpool University Medical School	2015 - 16
Lead for Year 4 Liverpool Undergraduates at Blackpool Victoria Hospital	2014 - 17
Cardiology Research Lead, Blackpool Victoria Hospital	2014 - 17
Honorary Senior Clinical Lecturer, University of Buckingham	2012
Honorary Teacher, Liverpool University Medical School	2012 - 15
Consultant Cardiologist with practicing privileges, Spire Fylde Coast Hospital	2011 -
Consultant Cardiologist, Lancashire Cardiac Centre, Blackpool Victoria Hospital	2010 -

QUALIFICATIONS

FRCP (UK)	2013
CCT in Cardiology + General (Internal) Medicine	2009
DM (Oxon)	2006
MRCP (UK)	1998
MA (Oxon)	1996
BM BCh	1995
BA (Hons) degree in Physiological Sciences [Class II (i)]	1992

EDUCATION

Green College, Oxford University	1992-95
St. John's College, Oxford University	1989-92
The Manchester Grammar School, Manchester	1982-89

PRIZES, FELLOWSHIPS and AWARDS

NIHR Commercial Research Delivery Centre: Blackpool (Project Lead and Clinical Director), part of NIHR Infrastructure (£3.5M over 7 years)	2025 -
Co-PI on successful 3-year BHF project grant (PG/23/11456). "A comprehensive analysis of HDL dysfunction: towards new markers and targets for atherosclerosis" (£254,601), awarded August 2023	2023
Collaborator on successful NIHR Biomedical Research Centre Bid: Manchester (£750k seed funding over 5 years)	2022
Project lead on a successful Academic Health Sciences Network System Transformation Fund award (913-PR692-LSClSTF). "Improving secondary prevention lipid management across Lancashire and South Cumbria" (£121,586)	2022
NW GMSA (NW Genomic Medicine Service Alliance) lipid clinic grant to expand testing for Familial Hypercholesterolaemia (project lead) (£50k)	2022
Co-PI on successful MRC Grant (MR/S018905/1) on microvascular angina "MICA: A developmental trial of personalised medicine for repurposing zibotentan, Selective endothelin A receptor blocker, in microvascular angina" (£2,714,383)	2019
NIHR Patient Recruitment Centre: Blackpool (Project Lead and Clinical Director) (£2M over 5 years)	2019-25
Sanofi industry grant for Blackpool Lipid Clinic Nurse (£55k)	2018-19
EAPCI Interventional Training Fellowship, Zurich, Switzerland	2007-8
ESC Young Investigator Finalist Award, Population Sciences	2004
West London Research Network (WeLReN) Project Grant (£10k)	1999
Oxford University Medical School Cardiology Prize	1994

PERSONAL STATEMENT

I am a fully trained interventional cardiologist with extensive general cardiology experience. My Certificate for Completion of Specialist Training (CCT) is in both Cardiology and General (Internal) Medicine. I have a busy clinical job but also fit in an active interest in lipid management, medical education, research and medico-legal work.

CURRENT APPOINTMENT

Clinical Cardiology

I am a Consultant Interventional Cardiologist at the Lancashire Cardiac Centre, a large tertiary cardiology unit. My weekly clinical responsibilities include 3 cath lab sessions, one out-patient clinic and 2 ward rounds. I am the Cardiologist of the Week one week in twenty-one, assessing and managing all in-patient cardiology referrals that week, undertaking daily ward rounds, reviewing referrals, attending ITU and managing Cardiology Advice and Guidance referrals. I am the Consultant on call for Cardiology on a one-in-nine rota, undertaking primary PCI procedures as part of the regional 24/7 primary PCI service. I undertake approximately 200 diagnostic angiograms and 150 coronary interventional procedures per year, including $_{c}$60 primary PCI procedures. I undertake complex PCI including left main stem, bifurcations and CTOs. My interventional mortality and MACE rates have always been below expected rates, according to BCIS data. I am the local lead for microvascular angina seeing regional referrals and undertaking invasive microvascular assessments where appropriate, having set up these assessments locally. I have performed >150 such studies to date both clinically and as part of clinical research.

Lipids

I have been interested in the management of patients with hyperlipidaemia for many years. In 2016 I wrote the regional CCG hypercholesterolaemia management guidelines. In 2017 I wrote a successful Trust business case to set up and run a new Blackpool Lipid Clinic at the hospital, treating patients with hyperlipidaemia. I trained an Advanced Practitioner and wrote the Trust guidelines. In 2019 I wrote a further successful business case expanding the clinic from monthly clinics to 5 clinics per week. I have set up and chair a weekly lipid clinic MDT. I have recruited two more Consultants to lipid clinic patients, including a Chemical Pathologist. In 2021 together with the North West Genomics Service I set up the facility for the lipid clinic to undertake genetic testing and cascade genetic testing for patients with possible familial hypercholesterolaemia (FH) and we have already diagnosed more than 150 local patients with FH to date. I have raised more than £100k from industry and the North West Genomic Medicine Service Alliance to further grow the service. I have worked on a number of research projects with the Innovation Agency, the ICB, Industry and General Practice to look at screening for FH within local general practices and to write region-wide pathways for diagnosing and managing hyperlipidaemia both in general practice and in secondary care. I am a member of the Lancashire and South Cumbria Cardiac Network cardiovascular disease prevention subgroup. From 2022-2023 I was the lipid lead for Lancashire and South Cumbria.

Education

I am very involved in education. Until 2014 I was the clinical tutor for cardiology, responsible for the junior cardiology induction and education. From 2010 to 2012 I helped organise and run 6 training days for interventional SpRs from the Merseyside and North West Deaneries with Deanery support. From 2014-2017 I was the Trust's lead responsible for the Year 4 Liverpool Medical School Students attached to Blackpool (40-48 per year). I helped organise induction, managed the planning and delivery of the curriculum, helped organise the teaching programme and helped with pastoral care. In 2015 I helped set up the new year 4 curriculum, with excellent student and staff feedback. In 2017 I helped organise a Liverpool University quality visit to Blackpool, receiving excellent feedback.

I regularly teach and/or supervise medical students, junior doctors, nurses and GPs. I have supervised a number of university projects. I teach radiography students at Salford University. I have taught on the PCI simulators at the BCS annual scientific meeting on more than 7 occasions and have been on the faculty of several national Cardiology and/or PCI meetings including the British Cardiovascular Society Annual Conferences.

Research

From 2014-2017 I was the Cardiology Research lead with overall responsibility for more than 10 research studies at any one time, helping manage the roles of 5 research nurses and 2 research fellows. Over the past 10 years I have been the local Principal Investigator (PI) for >20 NIHR portfolio studies, recruiting over 1000 patients.

In April 2017 I became the Director of Research, Development and Innovation for the Trust, chairing the R&D committee. I run the R&D Department, a 60 WTE department responsible for R&D activity at the Trust, working closely with local PIs, sponsors, commercial companies, and NIHR organisations. Blackpool Teaching Hospitals (BTH) has been the third highest recruiter to NIHR portfolio studies in the North West Coast for three of the past four years and the highest recruiters to commercial trials for each the past four years, generating >£1M of commercial research income per year on average. I have ensured PPIEP and Lancaster University representation on the R&D committee to help support engagement.

In 2019 I wrote the successful bid for Blackpool to become one of only 5 NIHR National Patient Recruitment Centres, becoming the Director of the PRC: Blackpool when it opened in June 2020, now part of formal NIHR Infrastructure, to specifically undertake late-phase commercial research, offering a concierge-like service to patients. Since becoming a PRC, BTH has been the highest recruiter to NIHR portfolio commercial studies within the North West Coast region, accounting for 22.2% of all regional commercial recruits, and has been the highest recruiter of the 5 PRCs to commercial studies, with excellent patient and industry feedback. We recruited 819 patients into Covid-19 vaccine trials, including the world's first Novavax phase III trial patient.

In 2022 BTH became a member of the NIHR Health Informatics Collaborative (HIC), contributing to big data analysis, with access to large national datasets. I attend the NIHR HIC: Cardiovascular steering group and have helped plan projects and have had posters presented at National Cardiovascular meetings.

In 2023 BTH became a member of the NIHR Biomedical Research Centre (BRC), supporting original basic science research. I attend the Strategic Executive Committee. BTH receive £150k per year from the BRC to support original research. BTH gave out 4 Trust BRC grants last year to Trust staff members to support original research with more planned for this year; has received two recent grants supported by the BRC (Innovate UK and BHF), including my HDL cholesterol trial, and currently recruits to BRC supported NIHR portfolio trials. BTH R&D is currently supporting 2 staff members to undertake PhDs at Lancaster University, with a potential further PhD planned. BTH has been chosen as an exemplar BRC impact case, showing the impact of BRC funding in growing research capacity and capabilities at the Trust to be showcased nationally.

We work closely with the Blackpool Council HDRC developing social determinants of health research and have recently appointed an "External Liaison" position to support PPIEP development and community and local council research opportunities, including local schools.

In July 2024 I submitted a bid for BTH to become an NIHR Commercial Research Delivery Centre (CRDC), the next generation from PRCs, which was successful.

In December 2024 I became an Honorary Professor of Cardiology at Lancaster University.

My own research interests include epidemiology, atherosclerosis, acute coronary syndromes, platelet-function testing, coronary physiology and microvascular angina. I am a co-applicant on a successful £2.7M MRC grant assessing targeted therapy in microvascular angina. I am a co-applicant on a BHF funded project grant studying dysfunctional HDL cholesterol to identify markers for cardiovascular disease status and risk, working with Lancaster University. I have published extensively over the past 3 years (>20 original publications since 2022), including *New Eng J Med* (impact factor 96.2) and *Circulation* (impact factor 39.9) original papers.

Committee Work

Blackpool Teaching Hospitals Venous Thromboembolism Committee Member	2012-14
Blackpool Teaching Hospitals Education Committee Member	2014-17
Blackpool Teaching Hospitals R&D Committee Member	2014 - present
Blackpool Teaching Hospitals R&D Committee Chairman	2017 - present
NIHR NWC Partnership Board Committee Member	2017 - present
NIHR-BHF National Coronary Microvascular Dysfunction Group	2020 - present
NIHR PRC Programme Board Committee Member	2021 - present
NIHR NWC Research Alignment Group Member	2022 - present
NIHR HIC Cardiovascular Steering Group	2022 - present
NIHR BRC: Manchester Strategic Executive Member	2023 - present
L&SC Integrated Care Board R&I Collaborative Member	2023 - present
L&SC Cardiac Network cardiovascular disease prevention subgroup	2023 – present
NIHR CRDC Directors Group member	2025 - present

Medico-legal Work

I have undertaken medico-legal work including clinical negligence work as an expert witness since 2013, regularly writing medical reports for solicitors and seeing clients where appropriate. I have written reports for the CQC and local Coroner. I produce approximately 15 reports per year. The current split between claimants and defendants is 70:30. I have experience preparing statements with the other party. I have not had to attend trial to date.

EMPLOYMENT HISTORY

Feb 2010 to Present	LANCASHIRE CARDIAC CENTRE ***Consultant Cardiologist***
Aug 2009 to Jan 2010	LIVERPOOL HEART AND CHEST HOSPITAL ***Post CCT Interventional Fellow***
Oct 2008 to July 2009	HAMMERSMITH HOSPITAL ***Senior Specialist Registrar in Cardiology***
Oct 2007 Sep 2008	TRIEMLI HOSPITAL, ZURICH, SWITZERLAND ***EAPCI/ESC Interventional Fellow***
June 2006 Sep 2007	HAMMERSMITH HOSPITAL ***Cardiology Interventional Fellow and Specialist Registrar***
Oct 2005 June 2006	ROYAL FREE HOSPITAL ***SpR and Interventional Trainee in Cardiology and General Medicine***
Oct 2004 Sep 2005	ROYAL BROMPTON HOSPITAL ***SpR in Cardiology, Adult Congenital Heart Disease and Heart Failure***
Oct 2003 Sep 2004	HAREFIELD HOSPITAL ***SpR in Cardiology + Heart Failure/Transplant Medicine***
Oct 2002 Sep 2003	HEMEL HEMPSTEAD HOSPITAL ***SpR in Cardiology and General Medicine***
Feb 2002 Sep 2002	LUTON AND DUNSTABLE HOSPITAL ***SpR in Cardiology and General Medicine***
Sep 1999 to Jan 2002	NORTHWICK PARK HOSPITAL ***Cardiology Research Registrar***
Aug 1998 to July 1999	ROYAL BROMPTON HOSPITAL ***Senior SHO in Cardiology + Adult Intensive Care***
Aug 1996 to July 1998	NORTH STAFFORDSHIRE CITY GENERAL and ROYAL INFIRMARY HOSPITALS, STOKE-ON-TRENT ***SHO, General Medical Rotation***
Feb 1996 to July 1996	JOHN RADCLIFFE HOSPITAL, OXFORD ***House Officer, General, Vascular and Renal Transplant Surgery***
Aug 1995 to Jan 1996	FREEMAN HOSPITAL, NEWCASTLE-UPON-TYNE ***House Officer General Medicine and Gastroenterology***

PUBLICATIONS

Original Research

1. Morrow A, Young R, Abraham GR, Hoole S, Greenwood JP, Arnold JR El Shibly M, Shanmuganathan M, Ferreira V, Rakhit R, Galasko G et al. Zibotentan in microvascular angina: a randomized, placebo-controlled, cross-over trial. *Circulation* 2024; **150:** 1671-1683

2. V. Kunadian, H. Mossop, C. Shields, M. Bardgett, P. Watts, M.D. Teare, J. Pritchard, J. Adams-Hall, C. Runnett, D.P. Ripley, J. Carter, J. Quigley, J. Cooke, D. Austin, J. Murphy, D. Kelly, J. McGowan, M. Veerasamy, D. Felmeden, H. Contractor, S. Mutgi, J. Irving, S. Lindsay, G. Galasko *et al* Invasive Treatment Strategy for Older Patients with Myocardial Infarction. *N Engl J Med. 2024*; **391:** 1673-1684

3. Ryan M *et al* on behalf of the REVIVED-BCIS2 Investigators. Effect of PCI on Health Status in Ischemic Left Ventricular Dysfunction: Insights From REVIVED-BCIS2. *JACC Heart Fail* 2024; April 8th – online ahead of print.

4. Ezad SM *et al* on behalf of the REVIVED-BCIS2 Investigators. Impact of Anatomical and Viability-Guided Completeness of Revascularization on Clinical Outcomes in Ischemic Cardiomyopathy. *J Am Coll Cardiol* 2024; **84**: 340-350

5. van den Broek WWA, Gimbel ME, Hermanides RS, Runnett C, Storey RF, Knaapen P, Means ME, Oemrawsingh RM, Cooke J, Galasko G et *al* The impact of patient-reported frailty on cardiovascular outcomes in elderly patients after non-ST-acute coronary syndrome. *Int J Cardiol* 2024; **15**: 131940

6. Chivardi C *et al* on behalf of the REVIVED-BCIS2 Investigators. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial. *Circ Cardiovasc Qual Outcomes* 2024; **17**: e010533

7. Perera D *et al* on behalf of the REVIVED-BCIS2 Investigators. Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial. *JAMA Cardiol* 2023; **8**: 1154-1161

8. Wong KYK *et al*. Effectiveness of out-patient based acute heart failure care: a pilot randomised controlled trial. *Acta Cardiol* 2023;**78**: 828-837

9. Wout van den Broek, Marieke Gimbel, Dean Chan Pin Yin, Jaouad Azzahhafi, Renicus Hermanides, Craig Runnet, Robert Storey, David Austin, Rohit Oemrawsingh, Justin Cooke, Gavin Galasko *et al*. Conservative versus invasive management of elderly patients with non-ST-elevation myocardial infarction: Insights from the International POPular Age Registry. *J Clin Med* 2023; **12**: 5450

10. Perera D *et al* on behalf of the REVIVED-BCIS2 Investigators. Arrhythmia and death following percutaneous revascularisation in ischemic left ventricular dysfunction: prespecified analyses from the REVIVED-BCIS2 Trial. *Circulation* 2023; **148**: 862-871

11. Nadarajah R *et al* on behalf of the NSTEMI investigator group. Presentation, care and outcomes of patients with NSTEMI according to World Bank country income classification:

the ACVC-EAPCI EORP NSTEMI Registry of the European Society of Cardiology. *Eur Heart J Qual Care Clin Outcomes* 2023; **9**: 552-563

12. Nadarajah R *et al* on behalf of the NSTEMI investigator group. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infarction (NSTEMI) Registry. *Eur Heart J Qual Care Clin Outcomes* 2022; **9**: 8-15

13. Romiti GF *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. *BMC Med* 2022; **20**:326 p1-12

14. Perera D *et al* on behalf of the REVIVED-BCIS2 Investigators. Percutaneous revascularization for ischemic left ventricular dysfunction. *N Engl J Med* 2022; **387**: 1351-60

15. Proietti M *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing 2022; **51**: afac192

16. Boriani G *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10 220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. *Eur J Prev Cardiol* 2022; **29**: 1967-81

17. Ding WY *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. Europace 2022; **24**: 721-728

18. Perera D *et al* on behalf of the UK Coronary Microvascular Dysfunction Working Group. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute for Health Research Partnership. *Heart* 2022 Mar 22. Online ahead of print

19. Malavasi VL *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. *Eur J Clin Invest*. 2022 Mar 19. Online ahead of print.

20. Gragnano F *et al* on behalf of the GLOBAL LEADERS Investigators. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. *J Am Heart Assoc* 2022; 11(10): e024291

21. Ding WY *et al* on behalf of the ESC-EHRA-EORP–AF AF Long-Term General Registry Investigators. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. Eur J Clin Invest. 2022; 52(6): e13745

22. Ding WY *et al* on behalf of the ESC-EHRA-EORP–AF AF Long-Term General Registry

Investigators. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. Europace 2022; **24**: 721-728

23. Proietti M *et al* on behalf of the ESC-EHRA-EORP–AF Long-Term General Registry Investigators. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. *BMC Med* 2021; 19(1): 256

24. Debski M, Abdelaziz H, Sanderson J *et al*. Mental Health Outcomes Among British Healthcare Workers - Lessons From the First Wave of the Covid-19 Pandemic. *J Occup Environ Med* 2021; **63**: e549–e555

25. Proietti MP *et al* on behalf of the ESC-EORP Atrial Fibrillation Long-Term Registry Investigators Group. Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. *Europace* 2021; **23**: 174-183

26. Morrow AJ, Ford TJ, Mangion K, Kotecha T, Rakhit R, Galasko G *et al* Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial. *Am Heart J* 2020; **229**: 70-80

27. Jennings CS, Kotseva K, Bassett P, Adamska A, Wood D on behalf of the ASPIRE-3-PREVENT Investigators. ASPIRE-3-PREVENT: a cross-sectional survey of preventive care after a coronary event across the UK. *Open Heart*; 2020; **7(1)**: e001196

28. Garg S, Chichareon P, Kogame N, Takahashi K, Modolo R, Chang CC, Tomaniak M, Fath-Ordoubadi F, Anderson R, Oldroyd KG, Stables RH, Kukreja N, Chowdhary S, Galasko G *et al* Impact of established cardiovascular disease on outcomes in the randomized global leaders trial; *Catheter Cardiovasc Interv* 2020; **96**: 1369-78

29. Wojciuk J, Beijk MA, Goode G, Brack M, Galasko G, More R *et al*. Balloon-assisted tracking technique as 'a way forward' for transradial intervention. *Coron Artery Dis* 2019; **30**: 440-447

30. Vranckx P, Valgimigli M, Jüni P and the GLOBAL LEADERS Investigators *et al*. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. *Lancet* 2018; **392**: 940-949

31. Boriani G, Proietti M, Laroche C and the EORP-AF Long-Term General Registry Investigators *et al*. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. *Europace* 2018; **20**: 747-757

32. Poppe KK *et al* on behalf of The Echocardiographic Normal Ranges Meta-Analysis of the Left heart (EchoNorMAL) Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic Left Atrial and Ventricular Size, Left Ventricular Mass, and Systolic Function. The EchoNoRMAL Study. *JACC Cardiovasc Imaging*. 2015; **8**: 656-65

33. Doughty RN *et al* on behalf of The Echocardiographic Normal Ranges Meta-Analysis of the Left heart (EchoNorMAL) Collaboration. A meta-analysis of echocardiographic measurements of the left heart for the development of normative reference ranges in a large international cohort: the Echo NoRMAL study. *Eur Heart J Cardiovas Imaging* 2014; **15**: 341-348

34. Galasko G, Collinson PO, Barnes SC, Gaze D, Lahiri A, Senior R. Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population. *J Clin Pathol* 2007; **60**: 570-572

35. Galasko GIW, Barnes SC, Collinson P, Lahiri A, Senior R. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? *Eur Heart J* 2006; **27**: 193-200

36. Galasko GIW, Lahiri A, Barnes SC, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? *Eur Heart J* 2005; **26**: 2269-76

37. Galasko GIW, Senior R, Lahiri A. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction in the community - The Harrow Heart Failure Watch. *Heart* 2005; **91**: 595-600

38. Galasko GIW, Basu S, Lahiri A, Senior R. Is echocardiography a valid tool to screen for left ventricular systolic dysfunction in chronic survivors of acute myocardial infarction? A comparison with radionuclide ventriculography. *Heart* 2004; **90**: 1422-6

39. Barnes SC, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. *Ann Clin Biochem* 2004; **41**: 459-63

40. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. *Eur J Heart Fail* 2004; **6**: 365-8

41. Senior R, Galasko G, Hickman M, Jeetley P, Lahiri A. Community screening for left ventricular hypertrophy in patients with hypertension using hand-held echocardiography. *J Am Soc Echocardiogr* 2004; **17**: 56-61

42. Galasko GIW, Lahiri A, Senior. Portable echocardiography: an innovative tool in screening for cardiac abnormalities in the community. *Eur J Echocardiogr* 2003; **4**: 119-27

43. Galasko GIW, Basu S, Lahiri A, Senior R. A prospective comparison of echocardiographic wall motion score index and radionuclide ejection fraction in predicting outcome following acute myocardial infarction. *Heart* 2001; **86**: 271-6

44. Cooke F, Galasko G, Ramrakha V, Richards D, Rose A and Watkins J. Medical Students in General Practice. How do patients feel? *British Journal of General Practice* 1996; **46**: 361-362

Editorials/ Reviews

1. Galasko GIW, Baker CSR. Acute Cardiovascular Medicine. *Clin Med* 2007; **7**: 257-61

2. Galasko GIW, Baker CSR. Alcoholic Cardiomyopathy *Alcoholis* 2007; **26**: 2-3

3. Galasko GIW, Henein M. Direct access echocardiography. *Int J Cardiovasc Imaging* 2006; **22**: 29-31

4. Senior R, Galasko G. Cost-effective strategies to screen for left ventricular systolic dysfunction in the community - a concept. *Congest Heart Fail* 2005; **11**: 194-211

5. Collinson PO, Galasko G. Natriuretic peptides – physiology and clinical application. *CPD Clinical Biochemistry* 2003; **5**: 48-52

6. Senior R, Galasko G, McMurray JV, Mayet J. Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. *Heart* 2003; **89 Suppl 3**: iii24-8

7. Galasko GIW, Lahiri A. The non-invasive assessment of viable myocardium in ischaemic cardiomyopathy – a myriad of techniques. *Eur J Heart Fail* 2003; **5**: 217-27

8. Galasko GIW, Senior R. Portable echocardiography – a revolution in cardiac care? *Thoraxcentre J* 2001; **13**: 103-104

9. Galasko GIW, Lahiri A. Nuclear cardiology to assess the effect of medical therapy. *Q J Nucl Med* 2000; **44 (Suppl 1)**: 102-105

10. Galasko G. Cocaine, a risk factor for myocardial infarction. *J Cardiovasc Risk* 1997; **4**: 185-90

Case Reports / Letters

1. Cross B, Choudhury TR, Hindle M, Galasko G. Wasp sting induced STEMI with complete coronary artery occlusion: a case of Kounis syndrome. *BMJ Case Rep* 2017 Sep 7; 2017. pii: bcr-2017-221256.

2. Choudhury TR, Abdool MA, Galasko G. Energy drinks give you wings but also an abnormal exercise test. *BMJ Case Rep* 2017 Jul 27; 2017. pii: bcr-2017-220017

3. Attar MN, Bury R, Galasko G. Iatrogenic aortocoronary dissection successfully treated by coronary intervention. *Heart International* 2011; **6**: e15

4. Tanigawa J, Galasko G, Goktekin O, Di Mario C. A new steerable catheter to facilitate wire crossing through angulated chronic total occlusions. *EuroIntervention* May 2005

5. Galasko GIW, Dubowitz M, Senior R. Subarachnoid haemorrhage presenting as acute myocardial infarction with EMD arrest. *Heart* 2001; **86**: 340

6. Galasko G. Marfan Syndrome (letter). *J Med Gen* 1996; **33**: 1051

Book Chapter

Galasko GIW, Lahiri A. Other heart diseases: Heart failure, Cardiomyopathy, Valvular heart disease, Kawasaki disease. In Nuclear Cardiac Imaging: Principles and Applications. 3rd Edition. Iskandrian A and Verani M. Oxford University Press. 2003; 399-418

Published Abstracts

1. Kaura A, Chan WX, Galasko G et al. The prognostic significance of troponin following percutaneous coronary intervention in patients without acute coronary syndrome. British Cardiac Society Annual Scientific Meeting, June 2023

2. Galasko G. A comparison of two iFR methods to predict FFR (fractional flow reserve) - the **B**lackpool **C**oronary **i**FR **S**tudy (bcis). Heart 2016; **102**: Suppl 4: A10, Abstract 20

3. Galasko G. The instantaneous wave-free ratio (iFR) is an accurate predictor of fractional flow reserve (FFR) in adult coronary arteries so long as a grey zone or hybrid-approach is used and not individual cut-offs: The Blackpool Coronary iFR (BCIS) study. Heart 2015; **101**: Suppl 4 A131-A136, Abstract A68

4. Poppe KK, on behalf of the EchoNoRMAL Collaberation. What is normal left ventricular ejection fraction? A global individual person data meta-analysis of the distribution across ethnicity, gender and age. Eur Heart J 2013; **34 (Abstr Suppl)**: 348

5. Galasko GIW, Boesch C, Eberli F. The effect of age on the short- and long-term outcome of carotid artery stenting. *EuroIntervention* 2009; **5 (Suppl E)**: E55

6. Dwivedi G, Galasko G, Lim TK, Hayat S, Banfield A, Senior R. Can left atrial dimension determined with hand held echocardiography in community setting be used to predict long term risk of death or cerebro-vascular accident? *Eur J Echo* 2008; **9 (Suppl 1)**: S152-153

7. Galasko GIW, Frankel A, Baker CSR. Coronary artery disease in asymptomatic renal transplant assessment patients. *Heart* 2008; **94 (Suppl II)**: A121

8. Dwivedi G, Galasko GI, Banfield A, Lim TK, Senior R. Left atrial size determined by hand-held echocardiography predicts long-term adverse cardiac outcome in patients screened for heart failure in the community. *Heart* 2008; **94 (Suppl II)**: A68

9. Galasko GIW, Lahiri A, Barnes SC, Collinson P, Senior R. The prognosis of left ventricular systolic dysfunction in community subjects: a comparison with N-Terminal pro-brain natriuretic peptide. World Congress of Cardiology, Barcelona, 2006. P1391

10. Galasko GIW, Lahiri A, Senior R. The effect of weekly alcohol intake on left ventricular size and function. *Heart* 2006; **92 (Suppl II)**: A40

11. Galasko GIW, Lahiri A, Senior R. Ethnic differences in the prevalence and aetiology of left ventricular systolic dysfunction (lvd) in high-risk community subjects. *Heart* 2005; **91 (Suppl**

I): A58

12. Galasko G, Lahiri A, Barnes S, Collinson P, Senior R. The cost-effectiveness of screening for left ventricular systolic dysfunction in the general population and in high-risk subjects, a comparison of eight potential screening strategies. *Eur Heart J* 2004; **25 (Abstr Suppl)**: 120 [Young Investigator Award, Population Sciences]

13. Galasko GIW, Lahiri A, Barnes S, Collinson P, Senior R. What is the Most Cost-Effective Strategy to Screen for Left Ventricular Systolic Dysfunction in the Community: Natriuretic Peptides, Hand-Held Echocardiography, The ECG or Their Combination? A Comparison with Traditional Echocardiography. *Heart* 2004; **90 (Suppl II)**: A19

14. Galasko GI, Senior R, Barnes SC, Collinson P, Lahiri A. A simple clinical risk score to predict left ventricular systolic dysfunction in high-risk members of the general population. *Circulation* 2003; **108 (Suppl IV)**: IV-777

15. Galasko GI, Lahiri A, Barnes SC, Collinson P, Senior R. Screening for left ventricular systolic dysfunction in the community by use of hand-held echocardiography, N-terminal pro-brain natriuretic peptide or both, a cost-effectiveness analysis. *Circulation* 2003; **108 (Suppl IV)**: IV-715

16. Senior R, Galasko G, Hickman M, Jeetley P. Community screening for left-ventricular hypertrophy in hypertensive patients using hand-held ultrasonography. *Eur Heart J* 2003; **24(Abstr Suppl)**: 211

17. Galasko GIW, Senior R, Lahiri A. The prevalence and underlying aetiology of diastolic heart failure in the community? *Heart* 2003; **89(Suppl I)**: A33. Moderated Poster [Highest Ranking Abstracts – after Judges Choice Section]

18. Galasko GIW, Senior R, Lahiri A. The prevalence of diastolic heart failure in the community. *J Am Coll Cardiol* 2003; **41 (Suppl A)**: 149A

19. Galasko GIW, Barnes S, Gaze D, Collinson P, Senior R, Lahiri A. What is the normal range for N-terminal pro-brain natriuretic peptide levels in the community? *J Am Coll Cardiol* 2003; **41 (Suppl A)**: 222A

20. Galasko GIW, Lahiri A, Senior R. Is wall motion score index a valid measure of left ventricular systolic dysfunction in the normal population? *Circulation* 2002; **106 (Suppl II)**: II-557

21. Galasko GIW, Lahiri A, Senior R, Trawinski J, Baumann M. Can natriuretic peptides screen for left ventricular diastolic dysfunction in the community? *Eur Heart J* 2002; **23(Abstr Suppl)**: 80

22. Galasko GIW, Senior R, Lahiri A. Modelling left ventricular dysfunction in the community setting. *Eur Heart J* 2002; **23(Abstr Suppl)**: 79

23. Galasko GIW, Lahiri A, Senior R. Is wall motion score index a valid measure of left ventricular systolic dysfunction in the normal population? *Heart* 2002; **87(Suppl II)**: 26

24. Galasko GIW, Senior R, Lahiri A. The prevalence and aetiology of left ventricular systolic

dysfunction in a multi-ethnic community? *Heart* 2002; **87(Suppl II)**: 15

25. Galasko GIW, Lahiri A, Trawinski J, Baumann M, Senior R. Can natriuretic peptides screen for left ventricular diastolic dysfunction in the absence of left ventricular systolic dysfunction in the community? *Heart* 2002; **87(Suppl II)**: 12

26. Galasko GI, Senior R, Lahiri A. A simple model to predict left ventricular systolic dysfunction in a multi-ethnic community. *J Am Coll Cardiol* 2002; **39(Suppl A)**: 176A

27. Galasko GIW, Lahiri A, Senior R. Portable echocardiography: an innovative tool for community based heart failure screening programmes. *Circulation* 2001; **104(Suppl II)**: II-334

28. Galasko GIW, Basu S, Lahiri A, Senior R. A prospective comparison of echocardiographic ejection fraction and wall motion score index with radionuclide ejection fraction in predicting outcome following acute myocardial infarction. *Eur Heart J* 2001; **22(Abstr Suppl)**: 73

29. Galasko GIW, Senior R, Lahiri A. Left ventricular systolic dysfunction: its community prevalence, aetiology and underlying risk factors in a multi-ethnic community. *Eur Heart J* 2001; **22(Abstr Suppl)**: 712

30. Galasko GIW, Lahiri A, Senior R. Portable echocardiography - an innovative tool in the assessment of left ventricular dysfunction in the community. *Eur Heart J* 2001; **22(Abstr Suppl)**: 706. Invited for presentation in a Featured Research Session.

31. Galasko GIW, Lahiri A, Senior R. Portable echocardiography: an innovative tool in the assessment of heart failure in the community. *Heart* 2001; **85(Suppl I)**: 27

32. Galasko GIW. Asymptomatic left ventricular dysfunction: its community prevalence and aetiology – the Harrow Heart Failure Watch – an interim analysis. Accepted as a "showcase submission" to the Association of University Departments of General Practice Annual Scientific Meeting, February 2001

33. Jordan SJ, Galasko G, Padley S, Goldstraw P, Evans TW. ARDS following lobectomy: a unilateral phenomenon? *Thorax* 1999

34. Jordan SJ, Galasko G, Padley S, Goldstraw P, Evans TW. ARDS following lobectomy presents in the contra-lateral lung. *Intensive Care Society* - London 1999

35. Cooke F, Galasko G, Ramrakha V, Richards D, Rose A and Watkins J. Medical Students in General Practice Consultations. How do patients feel? Poster presentation at the Association of University Departments of General Practice Annual Scientific Meeting, July 1994

Journals Refereed

Am J Cardiol, BMC Cardiovascular Disorders, BMJ, Clinical Medicine, Circulation, Circulation – Heart Failure, Eur J Cardiothorac Surg, Eur J Echo, Heart, Int J Cardiol, J Inv Cardiol

Editor for 3 BMJ Best Practice articles 2020/21: NSTEMI, STEMI and unstable angina

PROFESSIONAL MEMBERSHIPS:
British Cardiovascular Society
British Cardiovascular Intervention Society
British Medical Association
Royal College of Physicians (UK)
Medical Protection Society

I am fully GCP Compliant